Review: Senescent Cancer-Associated Fibroblasts and SASP in Breast Cancer
This abstract describes a review of how senescent cancer-associated fibroblasts and their secreted SASP factors may promote breast cancer progression and how a proposed 'one-two punch' strategy aims to target them. [1]
Automatic summary · not editorially reviewed
The key findings
The review examines the contradictory role of senescence, focusing on senescent cancer-associated fibroblasts in breast cancer progression. [1]
The abstract says SASP creates an immunosuppressive, therapy-resistant tumor microenvironment that promotes cancer progression. [1]
The review discusses the proposed 'one-two punch approach' aimed at targeting senCAFs to counteract breast cancer progression. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Breast cancer tumor microenvironment, with focus on senescent cancer-associated fibroblasts
- Summary based on
- Study abstract
- Original publication
- October 9, 2026
Dual role of senescence in breast cancer
The review addresses cellular senescence, described as a typically persistent cell-cycle arrest after DNA damage, and its contradictory role in carcinogenesis. Inducing senescence in early-stage tumor cells has been shown to inhibit proliferation, while senescent cancer-associated fibroblasts (senCAFs) in the tumor microenvironment have been linked to adverse consequences. The review focuses on senCAFs in breast cancer progression.
Supporting source [1]
SASP factors and immune suppression in the review
According to the abstract, senescent cells are major producers of the senescence-associated secretory phenotype (SASP), which creates an immunosuppressive, therapy-resistant tumor microenvironment that promotes cancer progression. The review covers key SASP effector molecules — TGF-β, IL-6, MMPs, CXCL12 and OPN — reported to trigger epithelial-mesenchymal transition and suppress antitumor immunity, including natural killer (NK) cell function. It also examines paracrine and autocrine loops such as the OPN and CXCL12 axis.
Supporting source [1]
Proposed one-two punch strategy against senCAFs
The abstract states that the review discusses innovative strategies of the proposed 'one-two punch approach', designed to target senCAFs with the aim of counteracting breast cancer progression and improving prognosis for patients. The abstract does not report study design, sample, follow-up or outcome data, and it does not establish that such a strategy is validated or clinically available.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. The abstract reports no study design, sample size, follow-up or outcome data, and the proposed strategy is not shown to be validated or clinically available.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bogachek M, Sergeevichev D, Leonteva A, Pinova A, Richter V, Nushtaeva A. · europepmc.org · October 9, 2026